Contrast-enhanced ultrasound for liver imaging: Recent advances

Current Pharmaceutical Design

Volumn 18, Issue 15, 2012, Pages 2236-2252

  Salvatore, Veronica ^a   Borghi, Alberto ^a   Piscaglia, Fabio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Contrast Quantification; Contrast Enhanced Ultrasonography; Fusion Imaging; Liver Tumor Diagnosis; Microbubbles

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOTOXIC AGENT; GADOLINIUM ETHOXYBENZYL DIETHYLENETRIAMINE PENTAACETIC ACID; IODINATED CONTRAST MEDIUM; IODINATED POPPYSEED OIL; PERFLUBUTANE; RADIOPHARMACEUTICAL AGENT; SONOVUE; SORAFENIB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALBUMINURIA; ARTICLE; BILE DUCT DISEASE; CHEMOEMBOLIZATION; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCED ULTRASONOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIARRHEA; ECHOGRAPHY; FATTY LIVER; GRAFT FAILURE; HUMAN; KUPFFER CELL; LIVER; LIVER ABSCESS; LIVER ARTERY THROMBOSIS; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FOCAL NODULAR HYPERPLASIA; LIVER HEMANGIOMA; LIVER HEMATOMA; LIVER INJURY; LIVER METASTASIS; LIVER TRANSPLANTATION; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPERATING ROOM; PORTAL VEIN THROMBOSIS; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIODIAGNOSIS; RADIOFREQUENCY ABLATION; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; THROMBOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CONTRAST MEDIA; HUMANS; IMAGING, THREE-DIMENSIONAL; KUPFFER CELLS; LIVER DISEASES; LIVER NEOPLASMS; MICROBUBBLES; SENSITIVITY AND SPECIFICITY;

EID: 84860137834     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212800099892     Document Type: Article

References (144)

1. Gaiani S, Volpe L, Piscaglia F, Bolondi L. Vascularity of liver tumors and recent advances in doppler ultrasound. J Hepatol 2001; 34: 474-482.
2. Blomley MJ, Albrecht T, Cosgrove DO, et al. Improved imaging of liver metastases with stimulated acoustic emission in the late phase of enhancement with the US contrast agent SH U 508A: early experience. Radiology 1999; 210: 409-416.
3. Wilson SR, Greenbaum LD, Goldberg BB. Contrast-enhanced ultrasound: what is the evidence and what are the obstacles? AJR Am J Roentgenol 2009; 193: 55-60.
4. Piscaglia F, Bolondi L. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol 2006; 32: 1369-1375.
5. Piscaglia F, Leoni S, Cabibbo G, et al. Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. Dig Liver Dis 2010; 42: 729-734.
6. Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010; 59: 638-644.
7. Sontum PC. Physicochemical characteristics of Sonazoid, a new contrast agent for ultrasound imaging. Ultrasound Med Biol 2008; 34: 824-833.
8. Kawada N, Ohkawa K, Tanaka S, et al. Improved diagnosis of well-differentiated hepatocellular carcinoma with gadolinium ethoxybenzyl diethylene triamine pentaacetic acid-enhanced magnetic resonance imaging and Sonazoid contrast-enhanced ultra-sonography. Hepatol Res 2010; 40: 930-936.
9. Yoshikawa S, Iijima H, Saito M, et al. Crucial role of impaired Kupffer cell phagocytosis on the decreased Sonazoid-enhanced echogenicity in a liver of a nonalchoholic steatohepatitis rat model. Hepatol Res 2010; 40: 823-831.
10. Albrecht T, Blomley M, Bolondi L, et al. Guidelines for the use of contrast agents in ultrasound. January 2004. Ultraschall Med 2004; 25: 249-256.
11. Claudon M, Cosgrove D, Albrecht T, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. Ultraschall Med 2008; 29: 28-44.
12. Quaia E. The real capabilities of contrast-enhanced ultrasound in the characterization of solid focal liver lesions. Eur Radiol 2011; 21: 457-462.
13. Trillaud H, Bruel JM, Valette PJ, et al. Characterization of focal liver lesions with SonoVue-enhanced sonography: international multicenter-study in comparison to CT and MRI. World J Gastro-enterol 2009; 15: 3748-3756.
14. Seitz K, Strobel D, Bernatik T, et al. Contrast-Enhanced Ultrasound (CEUS) for the characterization of focal liver lesions - prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial). Parts of this manuscript were presented at the Ultrasound Dreilandertreffen 2008, Davos. Ultraschall Med 2009; 30: 383-389.
15. Seitz K, Bernatik T, Strobel D, et al. Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions in clinical practice (DEGUM Multicenter Trial): CEUS vs. MRI--a prospective comparison in 269 patients. Ultraschall Med 2010; 31: 492-499.
16. Strobel D, Seitz K, Blank W, et al. Contrast-enhanced ultrasound for the characterization of focal liver lesions--diagnostic accuracy in clinical practice (DEGUM multicenter trial). Ultraschall Med 2008; 29: 499-505.
17. Li R, Zhang X, Hua X, et al. Real-time contrast-enhanced ultra-sonography of resected and immunohistochemically proven hepatic angiomyolipomas. Abdom Imaging 2010; 35: 676-682.
18. Ignee A, Piscaglia F, Ott M, Salvatore V, Dietrich CF. A benign tumor of the liver mimicking malignant liver disease--cholangiocellular adenoma. Scand J Gastroenterol 2009; 44: 633-636.
19. Brancatelli G, Federle MP, Blachar A, Grazioli L. Hemangioma in the cirrhotic liver: diagnosis and natural history. Radiology 2001; 219: 69-74.
20. Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hy-povascular hepatocellular carcinoma. Hepatology 2005; 42: 27-34.
21. Piscaglia F, Lencioni R, Sagrini E, et al. Characterization of focal liver lesions with contrast-enhanced ultrasound. Ultrasound Med Biol 2010; 36: 531-550.
22. Celli N, Gaiani S, Piscaglia F, et al. Characterization of liver lesions by real-time contrast-enhanced ultrasonography. Eur J Gas-troenterol Hepatol 2007; 19: 3-14.
23. Laghi F, Catalano O, Maresca M, Sandomenico F, Siani A. Indeterminate, subcentimetric focal liver lesions in cancer patients: additional role of contrast-enhanced ultrasound. Ultraschall Med 2010; 31: 283-288.
24. Murphy-Lavallee J, Jang HJ, Kim TK, Burns PN, Wilson SR. Are metastases really hypovascular in the arterial phase? The perspective based on contrast-enhanced ultrasonography. J Ultrasound Med 2007; 26: 1545-1556.
25. Piscaglia F, Corradi F, Mancini M, et al. Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. BMC Cancer 2007; 7: 171.
26. Massironi S, Conte D, Sciola V, et al. Contrast-enhanced ultra-sonography in evaluating hepatic metastases from neuroendocrine tumors. Dig Liver Dis 2010; 42: 635-641.
27. Boozari B, Soudah B, Rifai K, et al. Grading of hypervascular hepatocellular carcinoma using late phase of contrast enhanced sonography-A prospective study. Dig Liver Dis 2011; 43: 484-490.
28. Zhou JH, Li AH, Cao LH, et al. Haemodynamic parameters of the hepatic artery and vein can detect liver metastases: assessment using contrast-enhanced ultrasound. Br J Radiol 2008; 81: 113-119.
29. Chen LD, Xu HX, Xie XY, et al. Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound. Eur Radiol 2010; 20: 743-753.
30. Xu HX, Chen LD, Xie XY, et al. Enhancement pattern of hilar cholangiocarcinoma: contrast-enhanced ultrasound versus contrast-enhanced computed tomography. Eur J Radiol 2010; 75: 197-202.
31. Wilson SR, Kim TK, Jang HJ, Burns PN. Enhancement patterns of focal liver masses: discordance between contrast-enhanced sono-graphy and contrast-enhanced CT and MRI. AJR Am J Roentgenol 2007; 189: W7-W12.
32. Harris MA, Johnson TR, Weinberg PM, Fogel MA. Delayed-enhancement cardiovascular magnetic resonance identifies fibrous tissue in children after surgery for congenital heart disease. J Tho-rac Cardiovasc Surg 2007; 133: 676-681.
33. Murakami T, Nakamura H, Tsuda K, et al. Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: pathologic correlation study. J Magn Reson Imaging 1995; 5: 165-170.
34. Foschi FG, Dall'Aglio AC, Marano G, et al. Role of contrast-enhanced ultrasonography in primary hepatic lymphoma. J Ultrasound Med 2010; 29: 1353-1356.
35. Luo XL, Liu D, Yang JJ, Zheng MW, Zhang J, Zhou XD. Primary gastrointestinal stromal tumor of the liver: a case report. World J Gastroenterol 2009; 15: 3704-3707.
36. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
37. Leoni S, Piscaglia F, Golfieri R, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepato-cellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010; 105: 599-609.
38. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the nonin-vasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97-104.
39. Kudo M. Early detection and characterization of hepatocellular carcinoma: value of imaging ultistep human hepatocarcinogene-sis. Intervirology 2006; 49: 64-69.
40. Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol 2009; 44 Suppl 19: 112-118.
41. Kumada T, Nakano S, Toyoda H, et al. Assessment of tumor hemodynamics in small hepatocellular carcinoma: comparison of Doppler ultrasonography, angiography-assisted computed tomography, and pathological findings. Liver Int 2004; 24: 425-431.
42. Nicolau C, Catala V, Vilana R, et al. Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: correlation with cellular differentiation. Eur Radiol 2004; 14: 1092-1099.
43. Liu GJ, Xu HX, Lu MD, et al. Correlation between enhancement pattern of hepatocellular carcinoma on real-time contrast-enhanced ultrasound and tumor cellular differentiation on histopathology. Br J Radiol 2007; 80: 321-330.
44. Jang HJ, Kim TK, Burns PN, Wilson SR. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology 2007; 244: 898-906.
45. Shaib YH, El-Serag HB, Nooka AK, et al. Risk factors for intrahe-patic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol 2007; 102: 1016-1021.
46. Chen LD, Xu HX, Xie XY, et al. Enhancement patterns of intrahe-patic cholangiocarcinoma: comparison between contrast-enhanced ultrasound and contrast-enhanced CT. Br J Radiol 2008; 81: 881-889.
47. D'Onofrio M, Vecchiato F, Cantisani V, et al. Intrahepatic peripheral cholangiocarcinoma (IPCC): comparison between perfusion ultrasound and CT imaging. Radiol Med 2008; 113: 76-86.
48. Xu HX, Liu GJ, Lu MD, et al. Characterization of focal liver lesions using contrast-enhanced sonography with a low mechanical index mode and a sulfur hexafluoride-filled microbubble contrast agent. J Clin Ultrasound 2006; 34: 261-272.
49. Vilana R, Forner A, Bianchi L, et al. Intrahepatic peripheral cho-langiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010; 51: 2020-2029.
50. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
51. Xu HX. Contrast-enhanced ultrasound in the biliary system: Potential uses and indications. World J Radiol 2009; 1: 37-44.
52. Vanbockrijck M, Kloppel G. Incidence and morphology of liver metastasis from extrahepatic malignancies to cirrhotic livers. Zen-tralbl Pathol 1992; 138: 91-96.
53. Wong GL, Xu HX, Xie XY. Detection of focal liver lesions in cir-rhotic liver using contrast-enhanced ultrasound. World J Radiol 2009; 1: 25-36.
54. Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40: 1352-1360.
55. Chopra S, Dodd GD, 3rd, Chintapalli KN, Leyendecker JR, Kara-han OI, Rhim H. Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dual-phase contrast-enhanced CT. AJR Am J Roentgenol 2001; 177: 381-387.
56. Bartolotta TV, Taibbi A, Midiri M, De Maria M. Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound. Abdom Imaging 2008; 33: 501-511.
57. Sparchez Z, Radu P, Anton O, Socaciu M, Badea R. Contrast enhanced ultrasound in assessing therapeutic response in ablative treatments of hepatocellular carcinoma. J Gastrointestin Liver Dis 2009; 18: 243-248.
58. Miyamoto N, Hiramatsu K, Tsuchiya K, Sato Y. Contrast-enhanced sonography-guided radiofrequency ablation for the local recurrence of previously treated hepatocellular carcinoma undetected by B-mode sonography. J Clin Ultrasound 2010; 38: 339-345.
59. Salvaggio G, Campisi A, Lo Greco V, Cannella I, Meloni MF, Caruso G. Evaluation of posttreatment response of hepatocellular carcinoma: comparison of ultrasonography with second-generation ultrasound contrast agent and multidetector CT. Abdom Imaging 2010; 35: 447-453.
60. Kisaka Y, Hirooka M, Kumagi T, et al. Usefulness of contrast-enhanced ultrasonography with abdominal virtual ultrasonography in assessing therapeutic response in hepatocellular carcinoma treated with radiofrequency ablation. Liver Int 2006; 26: 1241-1247.
61. Morimoto M, Nozawa A, Numata K, et al. Evaluation using contrast-enhanced harmonic gray scale sonography after radio frequency ablation of small hepatocellular carcinoma: sonographic-histopathologic correlation. J Ultrasound Med 2005; 24: 273-283.
62. Sasaki A, Kai S, Iwashita Y, Hirano S, Ohta M, Kitano S. Microsat-ellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. Cancer 2005; 103: 299-306.
63. Solbiati L, Ierace T, Tonolini M, Cova L. Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced ultrasound. Eur J Radiol 2004; 51 Suppl: S19-S23.
64. Andreana L, Kudo M, Hatanaka K, et al. Contrast-enhanced ultrasound techniques for guiding and assessing response to locore-gional treatments for hepatocellular carcinoma. Oncology 2010; 78 Suppl 1: 68-77.
65. Moschouris H, Malagari K, Papadaki MG, et al. Short-term evaluation of liver tumors after transarterial chemoembolization: limitations and feasibility of contrast-enhanced ultrasonography. Abdom Imaging 2011;
66. Lim HS, Jeong YY, Kang HK, Kim JK, Park JG. Imaging features of hepatocellular carcinoma after transcatheter arterial chemoem-bolization and radiofrequency ablation. AJR Am J Roentgenol 2006; 187: W341-W349.
67. Golfieri R, Cappelli A, Cucchetti A, et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology 2011; 53: 1580-1589.
68. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
69. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
70. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
71. Ponziani FR, Zocco MA, Campanale C, et al. Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol 2010; 16: 143-155.
72. Lencioni R, Caramella D, Sanguinetti F, Battolla L, Falaschi F, Bartolozzi C. Portal vein thrombosis after percutaneous ethanol injection for hepatocellular carcinoma: value of color Doppler sono-graphy in distinguishing chemical and tumor thrombi. AJR Am J Roentgenol 1995; 164: 1125-1130.
73. Rossi S, Ghittoni G, Ravetta V, et al. Contrast-enhanced ultrasono-graphy and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma. Eur Radiol 2008; 18: 1749-1756.
74. Piscaglia F, Gianstefani A, Ravaioli M, et al. Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. Liver Transpl 2010; 16: 658-667.
75. Torzilli G, Del Fabbro D, Palmisano A, Donadon M, Montorsi M. Contrast-enhanced intraoperative ultrasonography: a valuable and not any more monocentric diagnostic technique performed in different ways. Ann Surg 2007; 245: 152-3; author reply 152-153.
76. Sahani DV, Kalva SP, Tanabe KK, et al. Intraoperative US in patients undergoing surgery for liver neoplasms: comparison with MR imaging. Radiology 2004; 232: 810-814.
77. Torzilli G. Contrast-enhanced intraoperative ultrasonography in surgery for liver tumors. Eur J Radiol 2004; 51 Suppl: S25-S29.
78. Lu Q, Luo Y, Yuan CX, et al. Value of contrast-enhanced intraop-erative ultrasound for cirrhotic patients with hepatocellular carcinoma: a report of 20 cases. World J Gastroenterol 2008; 14: 4005-4010.
79. Torzilli G, Olivari N, Moroni E, et al. Contrast-enhanced intraop-erative ultrasonography in surgery for hepatocellular carcinoma in cirrhosis. Liver Transpl 2004; 10: S34-S38.
80. Leen E, Ceccotti P, Moug SJ, et al. Potential value of contrast-enhanced intraoperative ultrasonography during partial hepatec-tomy for metastases: an essential investigation before resection? Ann Surg 2006; 243: 236-240.
81. Torzilli G, Garancini M, Donadon M, Cimino M, Procopio F, Mon-torsi M. Intraoperative ultrasonographic detection of communicating veins between adjacent hepatic veins during hepatectomy for tumors at the hepatocaval confluence. Br J Surg 2010; 97: 1867-1873.
82. Inoue T, Kitano M, Kudo M, et al. Diagnosis of gallbladder diseases by contrast-enhanced phase-inversion harmonic ultrasono-graphy. Ultrasound Med Biol 2007; 33: 353-361.
83. Xie XH, Xu HX, Xie XY, et al. Differential diagnosis between benign and malignant gallbladder diseases with real-time contrast-enhanced ultrasound. Eur Radiol 2010; 20: 239-248.
84. Adamietz B, Wenkel E, Uder M, et al. Contrast enhanced sonogra-phy of the gallbladder: a tool in the diagnosis of cholecystitis? Eur J Radiol 2007; 61: 262-266.
85. Zheng RQ, Chen GH, Xu EJ, et al. Evaluating biliary anatomy and variations in living liver donors by a new technique: three-dimensional contrast-enhanced ultrasonic cholangiography. Ultrasound Med Biol 2010; 36: 1282-1287.
86. Xu EJ, Mao R, Zheng RQ, et al. Three-dimensional contrast-enhanced ultrasonic cholangiography: a new technique for delineation of the biliary tract in a liver donor. Liver Transpl 2009; 15: 1154-1156.
87. Mao R, Xu EJ, Li K, Zheng RQ. Usefulness of contrast-enhanced ultrasound in the diagnosis of biliary leakage following T-tube removal. J Clin Ultrasound 2010; 38: 38-40.
88. Piscaglia F, Nolsøe C, Dietrich C, et al. The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS). Update 2011 on non-hepatic applications. Ultraschall in Med 2011; DOI http://dx.doi.org/10.1055/s-0031-1281676.
89. Scalea TM, Rodriguez A, Chiu WC, et al. Focused Assessment with Sonography for Trauma (FAST): results from an international consensus conference. J Trauma 1999; 46: 466-472.
90. McGahan JP, Rose J, Coates TL, Wisner DH, Newberry P. Use of ultrasonography in the patient with acute abdominal trauma. J Ultrasound Med 1997; 16: 653-662; quiz 663-664.
91. Manetta R, Pistoia ML, Bultrini C, Stavroulis E, Di Cesare E, Masciocchi C. Ultrasound enhanced with sulphur-hexafluoride-filled microbubbles agent (SonoVue) in the follow-up of mild liver and spleen trauma. Radiol Med 2009; 114: 771-779.
92. Tang J, Li W, Lv F, et al. Comparison of gray-scale contrast-enhanced ultrasonography with contrast-enhanced computed tomography in different grading of blunt hepatic and splenic trauma: an animal experiment. Ultrasound Med Biol 2009; 35: 566-575.
93. Valentino M, Ansaloni L, Catena F, Pavlica P, Pinna AD, Barozzi L. Contrast-enhanced ultrasonography in blunt abdominal trauma: considerations after 5 years of experience. Radiol Med 2009; 114: 1080-1093.
94. Blomley MJ, Lim AK, Harvey CJ, et al. Liver microbubble transit time compared with histology and Child-Pugh score in diffuse liver disease: a cross sectional study. Gut 2003; 52: 1188-1193.
95. Moriyasu F, Itoh K. Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol 2009; 193: 86-95.
96. Numata K, Luo W, Morimoto M, et al. Contrast enhanced ultrasound of hepatocellular carcinoma. World J Radiol 2010; 2: 68-82.
97. Hatanaka K, Kudo M, Minami Y, et al. Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology 2008; 51 Suppl 1: 61-69.
98. Korenaga K, Korenaga M, Furukawa M, Yamasaki T, Sakaida I. Usefulness of Sonazoid contrast-enhanced ultrasonography for he-patocellular carcinoma: comparison with pathological diagnosis and superparamagnetic iron oxide magnetic resonance images. J Gastroenterol 2009; 44: 733-741.
99. Kudo M, Hatanaka K, Maekawa K. Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid in the management of hepatocellular carcinoma. Oncology 2010; 78 Suppl 1: 40-45.
100. Hatanaka K, Kudo M, Minami Y, Maekawa K. Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology 2008; 75 Suppl 1: 42-47.
101. Maruyama H, Takahashi M, Ishibashi H, et al. Ultrasound-guided treatments under low acoustic power contrast harmonic imaging for hepatocellular carcinomas undetected by B-mode ultrasonography. Liver Int 2009; 29: 708-714.
102. Shiozawa K, Watanabe M, Takayama R, et al. Evaluation of local recurrence after treatment for hepatocellular carcinoma by contrast-enhanced ultrasonography using Sonazoid: comparison with dynamic computed tomography. J Clin Ultrasound 2010; 38: 182-189.
103. Miyamoto N, Hiramatsu K, Tsuchiya K, Sato Y, Terae S, Shirato H. Sonazoid-enhanced sonography for guiding radiofrequency ablation for hepatocellular carcinoma: better tumor visualization by Kupffer-phase imaging and vascular-phase imaging after reinjec-tion. Jpn J Radiol 2009; 27: 185-193.
104. Muhi A, Ichikawa T, Motosugi U, et al. Diagnosis of colorectal hepatic metastases: Contrast-enhanced ultrasonography versus contrast-enhanced computed tomography versus superparamagnetic iron oxide-enhanced magnetic resonance imaging with diffusion-weighted imaging. J Magn Reson Imaging 2010; 32: 1132-1140.
105. Edey AJ, Ryan SM, Beese RC, Gordon P, Sidhu PS. Ultrasound imaging of liver metastases in the delayed parenchymal phase following administration of Sonazoid using a destructive mode technique (Agent Detection Imaging). Clin Radiol 2008; 63: 1112-1120.
106. De Giorgi U, Aliberti C, Benea G, Conti M, Marangolo M. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 2005; 11: 6171-6176.
107. Lassau N, Lamuraglia M, Chami L, et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 2006; 187: 1267-1273.
108. Lassau N, Chami L, Koscielny S, et al. Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest New Drugs 2010;
109. Peronneau P, Lassau N, Leguerney I, Roche A, Cosgrove D. Contrast ultrasonography: necessity of linear data processing for the quantification of tumor vascularization. Ultraschall Med 2010; 31: 370-378.
110. Gauthier TP, Averkiou MA, Leen EL. Perfusion quantification using dynamic contrast-enhanced ultrasound: the impact of dynamic range and gain on time-intensity curves. Ultrasonics 2011; 51: 102-106.
111. Williams R, Hudson JM, Lloyd BA, et al. Dynamic Microbubble Contrast-enhanced US to Measure Tumor Response to Targeted Therapy: A Proposed Clinical Protocol with Results from Renal Cell Carcinoma Patients Receiving Antiangiogenic Therapy. Radiology
112. Basu S, Mohandas KM, Peshwe H, Asopa R, Vyawahare M. FDG-PET and PET/CT in the clinical management of gastrointestinal stromal tumor. Nucl Med Commun 2008; 29: 1026-1039.
113. Lamuraglia M, Escudier B, Chami L, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Dop-pler ultrasound. Eur J Cancer 2006; 42: 2472-2479.
114. Lassau N, Koscielny S, Chami L, et al. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results. Radiology 2011; 258: 291-300.
115. Salvatore V, Borghi A, Sagrini E, et al. Quantification of enhancement of focal liver lesions during contrast-enhanced ultrasound (CEUS). Analysis of ten selected frames is more simple but as reliable as the analysis of the entire loop for most parameters. Eur J Radiol 2011;
116. Huang-Wei C, Bleuzen A, Bourlier P, et al. Differential diagnosis of focal nodular hyperplasia with quantitative parametric analysis in contrast-enhanced sonography. Invest Radiol 2006; 41: 363-368.
117. Leen E, Kumar S, Khan SA, et al. Contrast-enhanced 3D ultrasound in the radiofrequency ablation of liver tumors. World J Gas-troenterol 2009; 15: 289-299.
118. Luo W, Numata K, Morimoto M, et al. Differentiation of focal liver lesions using three-dimensional ultrasonography: retrospective and prospective studies. World J Gastroenterol 2010; 16: 2109-2119.
119. Luo W, Numata K, Morimoto M, et al. Three-dimensional contrast-enhanced sonography of vascular patterns of focal liver tumors: pilot study of visualization methods. AJR Am J Roentgenol 2009; 192: 165-173.
120. Luo W, Numata K, Morimoto M, et al. Focal liver tumors: characterization with 3D perflubutane microbubble contrast agent-enhanced US versus 3D contrast-enhanced multidetector CT. Radiology 2009; 251: 287-295.
121. Xu HX, Lu MD, Xie XH, et al. Three-dimensional contrast-enhanced ultrasound of the liver: experience of 92 cases. Ultrasonics 2009; 49: 377-385.
122. Numata K, Fukuda H, Ohto M, et al. Evaluation of the therapeutic efficacy of high-intensity focused ultrasound ablation of hepatocel-lular carcinoma by three-dimensional sonography with a perflubu-tane-based contrast agent. Eur J Radiol 2010; 75: e67-e75.
123. Gaiani S, Gramantieri L, Venturoli N, et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol 1997; 27: 979-985.
124. Piscaglia F, Zironi G, Gaiani S, et al. Relationship between splanchnic, peripheral and cardiac haemodynamics in liver cirrhosis of different degrees of severity. Eur J Gastroenterol Hepatol 1997; 9: 799-804.
125. Albrecht T, Blomley MJ, Cosgrove DO, et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999; 353: 1579-1583.
126. Lim AK, Taylor-Robinson SD, Patel N, et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005; 54: 128-133.
127. Lim AK, Patel N, Eckersley RJ, et al. Hepatic vein transit time of SonoVue: a comparative study with Levovist. Radiology 2006; 240: 130-135.
128. Abbattista T, Ridolfi F, Ciabattoni E, et al. Diagnosis of liver cirrhosis by transit-time analysis at contrast-enhanced ultrasonogra-phy. Radiol Med 2008; 113: 860-874.
129. Ridolfi F, Abbattista T, Marini F, et al. Contrast-enhanced ultrasound to evaluate the severity of chronic hepatitis C. Dig Liver Dis 2007; 39: 929-935.
130. Staub F, Tournoux-Facon C, Roumy J, et al. Liver fibrosis staging with contrast-enhanced ultrasonography: prospective multicenter study compared with METAVIR scoring. Eur Radiol 2009; 19: 1991-1997.
131. Piscaglia F, Salvatore V, Di Donato R, et al. Accuracy of Virtu-alTouch Acoustic Radiation Force Impulse (ARFI) imaging for the diagnosis of cirrhosis during liver ultrasonography. Ultraschall Med 2011; 32: 167-175.
132. Leen E, Goldberg JA, Robertson J, Sutherland GR, McArdle CS. The use of duplex sonography in the detection of colorectal hepatic metastases. Br J Cancer 1991; 63: 323-325.
133. Zhang H, He Y, Du L, Wu Y. Shorter hepatic transit time can suggest coming metastases: through-monitoring by contrast-enhanced ultrasonography? J Ultrasound Med 2010; 29: 719-726.
134. Singh AK, Nachiappan AC, Verma HA, et al. Postoperative imaging in liver transplantation: what radiologists should know. Radio-graphics 2010; 30: 339-351.
135. Wojcicki M, Post M, Pakosz-Golanowska M, et al. Vascular complications following adult piggyback liver transplantation with end-to-side cavo-cavostomy: a single-center experience. Transplant Proc 2009; 41: 3131-3134.
136. Zheng RQ, Mao R, Ren J, et al. Contrast-enhanced ultrasound for the evaluation of hepatic artery stenosis after liver transplantation: potential role in changing the clinical algorithm. Liver Transpl 2010; 16: 729-735.
137. Pareja E, Cortes M, Navarro R, Sanjuan F, Lopez R, Mir J. Vascular complications after orthotopic liver transplantation: hepatic artery thrombosis. Transplant Proc 2010; 42: 2970-2972.
138. Luo Y, Fan YT, Lu Q, Li B, Wen TF, Zhang ZW. CEUS: a new imaging approach for postoperative vascular complications after right-lobe LDLT. World J Gastroenterol 2009; 15: 3670-3675.
139. Hom BK, Shrestha R, Palmer SL, et al. Prospective evaluation of vascular complications after liver transplantation: comparison of conventional and microbubble contrast-enhanced US. Radiology 2006; 241: 267-274.
140. Berstad AE, Brabrand K, Foss A. Clinical utility of microbubble contrast-enhanced ultrasound in the diagnosis of hepatic artery occlusion after liver transplantation. Transpl Int 2009; 22: 954-960.
141. Piscaglia F, Cecilioni L, Gaiani S, et al. Use of perfusional angios-onography in liver transplantation and conservative management of post-transplant intra-hepatic pseudo-aneurysm. Transpl Int 2004; 17: 634-638.
142. Herold C, Reck T, Ott R, et al. Contrast-enhanced ultrasound improves hepatic vessel visualization after orthotopic liver transplantation. Abdom Imaging 2001; 26: 597-600.
143. Hakime A, Deschamps F, De Carvalho EG, Teriitehau C, Auperin A, De Baere T. Clinical evaluation of spatial accuracy of a fusion imaging technique combining previously acquired computed tomography and real-time ultrasound for imaging of liver metastases. Cardiovasc Intervent Radiol 2011; 34: 338-344.
144. Jung EM, Schreyer AG, Schacherer D, et al. New real-time image fusion technique for characterization of tumor vascularisation and tumor perfusion of liver tumors with contrast-enhanced ultrasound, spiral CT or MRI: first results. Clin Hemorheol Microcirc 2009; 43: 57-69.